A team of specialists examined new outcomes data related to the SAPIEN 3 Ultra transcatheter heart valve, sharing its findings in EuroIntervention.

As this new ablation technique continues to gain momentum, researchers are hoping to learn as much as possible about any potential side effects. 

After its initial release was limited to certain customers, the new-look catheter is now available in four different sizes throughout the United States.

Researchers examined data from 34 different studies, publishing their full systematic review and meta-analysis in JAMA Pediatrics.

Identifying patients with severe aortic stenosis who could potentially benefit from transcatheter aortic valve replacement (TAVR) is very important—but managing and tracking them over time can be quite a challenge.

When the ACC and AHA collaborated on new valvular heart disease guidelines in 2020, the two groups highlighted the importance of interventional treatment options such as TAVR. However, an estimated one-third of patients with severe aortic stenosis in the U.S. still lack a guideline-recommended treatment plan.

Although advanced imaging exams have proven benefits in defining disease severity, new data indicate that more sophisticated studies might not impact outcomes as much as previously thought. 

LivaNova PLC developed the new cardio-pulmonary system based on feedback from more than 300 perfusionists.